JP7419260B2 - ＮａｎｏＬｕｃ自殺基質としてのセレンテラジン化合物 - Google Patents

ＮａｎｏＬｕｃ自殺基質としてのセレンテラジン化合物 Download PDF

Info

Publication number
JP7419260B2
JP7419260B2 JP2020561071A JP2020561071A JP7419260B2 JP 7419260 B2 JP7419260 B2 JP 7419260B2 JP 2020561071 A JP2020561071 A JP 2020561071A JP 2020561071 A JP2020561071 A JP 2020561071A JP 7419260 B2 JP7419260 B2 JP 7419260B2
Authority
JP
Japan
Prior art keywords
sample
oplophorus
luciferase
oxo
benzyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020561071A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021523111A (ja
JP2021523111A5 (enExample
Inventor
ブロック ビンコウスキー
メアリー ピー ホール
トーマス マクライト
ジョエル ウォーカー
ウェンフイ チョウ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Promega Corp
Original Assignee
Promega Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Promega Corp filed Critical Promega Corp
Publication of JP2021523111A publication Critical patent/JP2021523111A/ja
Publication of JP2021523111A5 publication Critical patent/JP2021523111A5/ja
Application granted granted Critical
Publication of JP7419260B2 publication Critical patent/JP7419260B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/66—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving luciferase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/52—Use of compounds or compositions for colorimetric, spectrophotometric or fluorometric investigation, e.g. use of reagent paper and including single- and multilayer analytical elements
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • G01N33/533—Production of labelled immunochemicals with fluorescent label
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
    • G01N33/542—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with steric inhibition or signal modification, e.g. fluorescent quenching
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2458/00—Labels used in chemical analysis of biological material
    • G01N2458/15—Non-radioactive isotope labels, e.g. for detection by mass spectrometry

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Enzymes And Modification Thereof (AREA)
JP2020561071A 2018-05-01 2019-04-30 ＮａｎｏＬｕｃ自殺基質としてのセレンテラジン化合物 Active JP7419260B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862665346P 2018-05-01 2018-05-01
US62/665,346 2018-05-01
PCT/US2019/029975 WO2019213119A1 (en) 2018-05-01 2019-04-30 Coelenterazine compounds as nanoluc suicide substrates

Publications (3)

Publication Number Publication Date
JP2021523111A JP2021523111A (ja) 2021-09-02
JP2021523111A5 JP2021523111A5 (enExample) 2022-05-13
JP7419260B2 true JP7419260B2 (ja) 2024-01-22

Family

ID=66530467

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020561071A Active JP7419260B2 (ja) 2018-05-01 2019-04-30 ＮａｎｏＬｕｃ自殺基質としてのセレンテラジン化合物

Country Status (4)

Country Link
US (2) US11655247B2 (enExample)
EP (1) EP3788048A1 (enExample)
JP (1) JP7419260B2 (enExample)
WO (1) WO2019213119A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7653351B2 (ja) 2018-08-23 2025-03-28 プロメガ コーポレイション セレンテラジン類似体
IL318819A (en) 2018-10-03 2025-04-01 Promega Corp Compounds and methods for stabilizing cholinetyrazine and its derivatives
KR20230147105A (ko) * 2021-01-28 2023-10-20 진콴텀 헬스케어 (쑤저우) 씨오., 엘티디. 리가제 융합 단백질 및 그 응용
CN120051474A (zh) 2022-10-14 2025-05-27 普罗美加公司 腔肠素类似物
US20250206747A1 (en) 2023-12-20 2025-06-26 Promega Corporation Coelenterazine analogues

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012061529A1 (en) 2010-11-02 2012-05-10 Promega Corporation Novel coelenterazine substrates and methods of use
WO2017142852A1 (en) 2016-02-15 2017-08-24 Promega Corporation Coelenterazine analogues
JP7139330B2 (ja) 2016-12-01 2022-09-20 プロメガ コーポレイション 細胞不透過性セレンテラジンアナログ
JP7200102B2 (ja) 2016-11-01 2023-01-06 プロメガ コーポレイション エネルギー受容体に係留されたセレンテラジン類縁体

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7268229B2 (en) 2001-11-02 2007-09-11 Promega Corporation Compounds to co-localize luminophores with luminescent proteins
US8883486B2 (en) 2004-05-04 2014-11-11 Universite De Montreal Arrestin biosensor
US20080248511A1 (en) 2007-03-26 2008-10-09 Promega Corporation Methods to quench light from optical reactions
ES2795287T3 (es) 2009-05-01 2020-11-23 Promega Corp Luciferasas de Oplophorus sintéticas con mayor emisión de luz
CA2815381C (en) 2010-11-02 2019-03-19 Promega Corporation Coelenterazine derivatives and methods of using same
US9273343B2 (en) 2011-09-02 2016-03-01 Promega Corporation Compounds and methods for assaying redox state of metabolically active cells and methods for measuring NAD(P)/NAD(P)H
WO2013078244A1 (en) 2011-11-21 2013-05-30 Promega Corporation Carboxy x rhodamine analogs
CN104395306B (zh) 2012-03-02 2019-04-23 皮尔斯生物科技有限公司 作为生物分子的标记染料的吲哚衍生物
US9790537B2 (en) 2014-01-29 2017-10-17 Promega Corporation Quinone-masked probes as labeling reagents for cell uptake measurements
EP3099691B1 (en) 2014-01-29 2019-11-20 Promega Corporation Pro-substrates for live cell applications
EP3313846B1 (en) 2015-06-25 2020-05-06 Promega Corporation Thienopyrrole compounds and uses thereof as inhibitors of oplophorus-derived luciferases
JP7212612B2 (ja) 2016-07-28 2023-01-25 プロメガ コーポレイション セレンテラジン類縁体

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012061529A1 (en) 2010-11-02 2012-05-10 Promega Corporation Novel coelenterazine substrates and methods of use
WO2017142852A1 (en) 2016-02-15 2017-08-24 Promega Corporation Coelenterazine analogues
JP7200102B2 (ja) 2016-11-01 2023-01-06 プロメガ コーポレイション エネルギー受容体に係留されたセレンテラジン類縁体
JP7139330B2 (ja) 2016-12-01 2022-09-20 プロメガ コーポレイション 細胞不透過性セレンテラジンアナログ

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Bioconjugate Chemistry，2018年05月16日，29(6)，1922-1931, Supplementary Information
ERIC LINDBERG; ET AL，DEVELOPMENT OF CELL-IMPERMEABLE COELENTERAZINE DERIVATIVES，CHEMICAL SCIENCE，2013年，VOL:4, NR:12，PAGE(S):4395 - 4400，http://dx.doi.org/10.1039/c3sc51985f
MACIEJ ADAMCZYK; ET AL，SYNTHESIS OF 3,7-DIHYDROIMIDAZO[1,2[ALPHA]]PYRAZINE-3-ONES AND THEIR CHEMILUMINESCENT PROPERTIES，TETRAHEDRON，NL，ELSEVIER SCIENCE PUBLISHERS，2003年10月06日，VOL:59,NR:41，PAGE(S):8129 - 8142，https://doi.org/10.1002/chin.200405126

Also Published As

Publication number Publication date
JP2021523111A (ja) 2021-09-02
US11655247B2 (en) 2023-05-23
US12570654B2 (en) 2026-03-10
EP3788048A1 (en) 2021-03-10
US20190337939A1 (en) 2019-11-07
WO2019213119A1 (en) 2019-11-07
US20230382908A1 (en) 2023-11-30

Similar Documents

Publication Publication Date Title
US12570654B2 (en) Nanoluc suicide substrates
JP7161475B2 (ja) 官能化ｎａｎｏｌｕｃ阻害剤
US11192894B2 (en) Cell impermeable coelenterazine analogues
US20210254128A1 (en) Coelenterazine analogues
JP7200102B2 (ja) エネルギー受容体に係留されたセレンテラジン類縁体
JP7664336B2 (ja) Ｏｐｌｏｐｈｏｒｕｓルシフェラーゼ由来生物発光性複合体の阻害剤
US20240059697A1 (en) Coelenterazine analogues

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220502

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220502

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230420

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230601

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230831

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231031

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20231211

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240110

R150 Certificate of patent or registration of utility model

Ref document number: 7419260

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150